TD Asset Management Inc Cuts Position in Edwards Lifesciences Corporation $EW

TD Asset Management Inc trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 743,640 shares of the medical research company’s stock after selling 167,546 shares during the period. TD Asset Management Inc owned approximately 0.13% of Edwards Lifesciences worth $58,160,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Wilson Asset Management International PTY Ltd. increased its position in Edwards Lifesciences by 5.6% during the 2nd quarter. Wilson Asset Management International PTY Ltd. now owns 146,506 shares of the medical research company’s stock valued at $11,458,000 after buying an additional 7,713 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in shares of Edwards Lifesciences by 17.0% during the second quarter. Wilmington Savings Fund Society FSB now owns 9,654 shares of the medical research company’s stock valued at $755,000 after acquiring an additional 1,404 shares in the last quarter. Axxcess Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 63.1% during the second quarter. Axxcess Wealth Management LLC now owns 12,977 shares of the medical research company’s stock valued at $1,015,000 after acquiring an additional 5,019 shares in the last quarter. NorthRock Partners LLC raised its position in shares of Edwards Lifesciences by 13.2% in the 2nd quarter. NorthRock Partners LLC now owns 22,705 shares of the medical research company’s stock worth $1,776,000 after purchasing an additional 2,650 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in Edwards Lifesciences by 12.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 26,461 shares of the medical research company’s stock worth $2,069,000 after purchasing an additional 2,966 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of EW opened at $72.92 on Thursday. The firm has a fifty day simple moving average of $77.72 and a two-hundred day simple moving average of $76.14. The firm has a market cap of $42.81 billion, a PE ratio of 10.49, a P/E/G ratio of 3.52 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Mizuho lifted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Finally, Piper Sandler boosted their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.06.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.